Evidence for a decrease in cardiovascular risk factors following recombinant growth hormone administration in abstinent anabolic-androgenic steroid users

Michael R. Graham, Julien S. Baker, Peter Evans, Andrew Kicman, David Cowan, David Hullin, Bruce Davies

Research output: Contribution to journalArticle

Abstract

Objectives
To determine whether six days recombinant human growth hormone (rhGH) in an abstinent anabolic-androgenic steroid (AAS) group had any cardiovascular and biochemical effects compared with a control group.

Methods
Male subjects (n = 48) were randomly divided, using a single blind procedure into two groups: (1) control group (C) n = 24, mean ± SD, age 32 ± 11 years; height 1.8 ± 0.06 m; (2) rhGH using group (0.058 IU kg−1 day−1) (GH) n = 24, mean ± SD, age 32 ± 9 years; height 1.8 ± 0.07 m. Physiological responses, anthropometry, arterial pulse wave velocity (APWV), blood pressure (BP), heart rate (HR), peak oxygen uptake (VO2 peak) and biochemical indices were investigated.

Results

Body mass index, fat-free mass index and VO2 peak significantly increased while body fat significantly decreased within GH (all P < 0.017). Insulin like growth factor-I significantly increased within GH (P < 0.017) and compared with C (P < 0.05). Serum sodium significantly increased (P < 0.017) and serum homocysteine, high sensitivity C-reactive protein, thyroid stimulating hormone and tetra-iodothyronine (T4), significantly decreased within GH (all P < 0.017). T4 significantly decreased compared with C (P < 0.05).

Arterial pulse wave velocity, peak and recovery systolic and diastolic BP, significantly decreased compared with C (P < 0.05). Resting HR and rate pressure product (RPP) significantly increased compared with C (P < 0.05).

Conclusion
The findings of this study suggest that short term use of rhGH may have beneficial effects on endothelial function and specific inflammatory markers of cardiovascular disease in abstinent AAS users, but may have an adverse effect on the cardiovascular system, as evidenced by the increase in resting RPP.
Original languageEnglish
Pages (from-to)201-209
Number of pages9
JournalGrowth Hormone & IGF Research
Volume17
Issue number3
DOIs
Publication statusPublished - 1 Jun 2007
Externally publishedYes

Fingerprint

Testosterone Congeners
Human Growth Hormone
Growth Hormone
Pulse Wave Analysis
Blood Pressure
Heart Rate
Pressure
Control Groups
Anthropometry
Homocysteine
Thyrotropin
Cardiovascular System
Serum
Insulin-Like Growth Factor I
C-Reactive Protein
Adipose Tissue
Cardiovascular Diseases
Sodium
Fats
Oxygen

Keywords

  • arterial pulse wave velocity
  • endothelial function
  • inflammation
  • growth hormone treatment

Cite this

Graham, Michael R. ; Baker, Julien S. ; Evans, Peter ; Kicman, Andrew ; Cowan, David ; Hullin, David ; Davies, Bruce. / Evidence for a decrease in cardiovascular risk factors following recombinant growth hormone administration in abstinent anabolic-androgenic steroid users. In: Growth Hormone & IGF Research. 2007 ; Vol. 17, No. 3. pp. 201-209.
@article{988b8a0b7fa44b68a3ab72fa4f94c036,
title = "Evidence for a decrease in cardiovascular risk factors following recombinant growth hormone administration in abstinent anabolic-androgenic steroid users",
abstract = "ObjectivesTo determine whether six days recombinant human growth hormone (rhGH) in an abstinent anabolic-androgenic steroid (AAS) group had any cardiovascular and biochemical effects compared with a control group.MethodsMale subjects (n = 48) were randomly divided, using a single blind procedure into two groups: (1) control group (C) n = 24, mean ± SD, age 32 ± 11 years; height 1.8 ± 0.06 m; (2) rhGH using group (0.058 IU kg−1 day−1) (GH) n = 24, mean ± SD, age 32 ± 9 years; height 1.8 ± 0.07 m. Physiological responses, anthropometry, arterial pulse wave velocity (APWV), blood pressure (BP), heart rate (HR), peak oxygen uptake (VO2 peak) and biochemical indices were investigated.ResultsBody mass index, fat-free mass index and VO2 peak significantly increased while body fat significantly decreased within GH (all P < 0.017). Insulin like growth factor-I significantly increased within GH (P < 0.017) and compared with C (P < 0.05). Serum sodium significantly increased (P < 0.017) and serum homocysteine, high sensitivity C-reactive protein, thyroid stimulating hormone and tetra-iodothyronine (T4), significantly decreased within GH (all P < 0.017). T4 significantly decreased compared with C (P < 0.05).Arterial pulse wave velocity, peak and recovery systolic and diastolic BP, significantly decreased compared with C (P < 0.05). Resting HR and rate pressure product (RPP) significantly increased compared with C (P < 0.05).ConclusionThe findings of this study suggest that short term use of rhGH may have beneficial effects on endothelial function and specific inflammatory markers of cardiovascular disease in abstinent AAS users, but may have an adverse effect on the cardiovascular system, as evidenced by the increase in resting RPP.",
keywords = "arterial pulse wave velocity, endothelial function, inflammation, growth hormone treatment",
author = "Graham, {Michael R.} and Baker, {Julien S.} and Peter Evans and Andrew Kicman and David Cowan and David Hullin and Bruce Davies",
year = "2007",
month = "6",
day = "1",
doi = "10.1016/j.ghir.2007.01.010",
language = "English",
volume = "17",
pages = "201--209",
journal = "Growth Hormone & IGF Research",
issn = "1096-6374",
publisher = "Elsevier B.V.",
number = "3",

}

Evidence for a decrease in cardiovascular risk factors following recombinant growth hormone administration in abstinent anabolic-androgenic steroid users. / Graham, Michael R.; Baker, Julien S.; Evans, Peter; Kicman, Andrew; Cowan, David; Hullin, David; Davies, Bruce.

In: Growth Hormone & IGF Research, Vol. 17, No. 3, 01.06.2007, p. 201-209.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evidence for a decrease in cardiovascular risk factors following recombinant growth hormone administration in abstinent anabolic-androgenic steroid users

AU - Graham, Michael R.

AU - Baker, Julien S.

AU - Evans, Peter

AU - Kicman, Andrew

AU - Cowan, David

AU - Hullin, David

AU - Davies, Bruce

PY - 2007/6/1

Y1 - 2007/6/1

N2 - ObjectivesTo determine whether six days recombinant human growth hormone (rhGH) in an abstinent anabolic-androgenic steroid (AAS) group had any cardiovascular and biochemical effects compared with a control group.MethodsMale subjects (n = 48) were randomly divided, using a single blind procedure into two groups: (1) control group (C) n = 24, mean ± SD, age 32 ± 11 years; height 1.8 ± 0.06 m; (2) rhGH using group (0.058 IU kg−1 day−1) (GH) n = 24, mean ± SD, age 32 ± 9 years; height 1.8 ± 0.07 m. Physiological responses, anthropometry, arterial pulse wave velocity (APWV), blood pressure (BP), heart rate (HR), peak oxygen uptake (VO2 peak) and biochemical indices were investigated.ResultsBody mass index, fat-free mass index and VO2 peak significantly increased while body fat significantly decreased within GH (all P < 0.017). Insulin like growth factor-I significantly increased within GH (P < 0.017) and compared with C (P < 0.05). Serum sodium significantly increased (P < 0.017) and serum homocysteine, high sensitivity C-reactive protein, thyroid stimulating hormone and tetra-iodothyronine (T4), significantly decreased within GH (all P < 0.017). T4 significantly decreased compared with C (P < 0.05).Arterial pulse wave velocity, peak and recovery systolic and diastolic BP, significantly decreased compared with C (P < 0.05). Resting HR and rate pressure product (RPP) significantly increased compared with C (P < 0.05).ConclusionThe findings of this study suggest that short term use of rhGH may have beneficial effects on endothelial function and specific inflammatory markers of cardiovascular disease in abstinent AAS users, but may have an adverse effect on the cardiovascular system, as evidenced by the increase in resting RPP.

AB - ObjectivesTo determine whether six days recombinant human growth hormone (rhGH) in an abstinent anabolic-androgenic steroid (AAS) group had any cardiovascular and biochemical effects compared with a control group.MethodsMale subjects (n = 48) were randomly divided, using a single blind procedure into two groups: (1) control group (C) n = 24, mean ± SD, age 32 ± 11 years; height 1.8 ± 0.06 m; (2) rhGH using group (0.058 IU kg−1 day−1) (GH) n = 24, mean ± SD, age 32 ± 9 years; height 1.8 ± 0.07 m. Physiological responses, anthropometry, arterial pulse wave velocity (APWV), blood pressure (BP), heart rate (HR), peak oxygen uptake (VO2 peak) and biochemical indices were investigated.ResultsBody mass index, fat-free mass index and VO2 peak significantly increased while body fat significantly decreased within GH (all P < 0.017). Insulin like growth factor-I significantly increased within GH (P < 0.017) and compared with C (P < 0.05). Serum sodium significantly increased (P < 0.017) and serum homocysteine, high sensitivity C-reactive protein, thyroid stimulating hormone and tetra-iodothyronine (T4), significantly decreased within GH (all P < 0.017). T4 significantly decreased compared with C (P < 0.05).Arterial pulse wave velocity, peak and recovery systolic and diastolic BP, significantly decreased compared with C (P < 0.05). Resting HR and rate pressure product (RPP) significantly increased compared with C (P < 0.05).ConclusionThe findings of this study suggest that short term use of rhGH may have beneficial effects on endothelial function and specific inflammatory markers of cardiovascular disease in abstinent AAS users, but may have an adverse effect on the cardiovascular system, as evidenced by the increase in resting RPP.

KW - arterial pulse wave velocity

KW - endothelial function

KW - inflammation

KW - growth hormone treatment

U2 - 10.1016/j.ghir.2007.01.010

DO - 10.1016/j.ghir.2007.01.010

M3 - Article

VL - 17

SP - 201

EP - 209

JO - Growth Hormone & IGF Research

JF - Growth Hormone & IGF Research

SN - 1096-6374

IS - 3

ER -